DNA hydrogels for glioblastoma: programmable, tumor-responsive nanocarriers for precision therapy and theranostics

Abstract Glioblastoma (GBM) is the most lethal primary brain tumor, with median survival of only 12–18 months despite maximal surgery, radiotherapy, and chemotherapy. Its infiltrative growth, molecular heterogeneity, and therapy resistance, compounded by the restrictive blood–brain barrier (BBB), se...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Pooyan Alizadeh, Negin Yousefi Chermehini, Aida Baharampour, Pedram Ghanavati, Armin Jahangiri Babadi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-12-01
coleção:	Cancer Nanotechnology
Assuntos:	Glioblastoma DNA hydrogels Nanomedicine Blood–brain barrier Targeted drug delivery Stimuli-responsive therapy
Acesso em linha:	https://doi.org/10.1186/s12645-025-00352-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!